Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.
Ulf
U
Landmesser
Arnold
A
von Eckardstein
John
J
Kastelein
John
J
Deanfield
Thomas F
TF
Lüscher
D054058:Acute Coronary Syndrome / Q000188:drug therapy; D000577:Amides; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D050197:Atherosclerosis / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors*; D008076:Cholesterol, HDL / Q000378:metabolism*; D057239:Early Termination of Clinical Trials; D004952:Esters; D006801:Humans; D023303:Oxazolidinones / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013438:Sulfhydryl Compounds / Q000627:therapeutic use
D000577:Amides; D000924:Anticholesteremic Agents; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D004952:Esters; D023303:Oxazolidinones; D011804:Quinolines; D013438:Sulfhydryl Compounds; C411602:dalcetrapib; C483909:torcetrapib; C530884:anacetrapib